Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Анализ 100 000 геномов опухолей человека раскрывает ландшафт мутационной нагрузки опухоли
Uri Y. Tabori, Siraj Mahamed Ali, Vincent A. Miller, David A. Fabrizio, Geoff A. Otto, Jared R. White, Brittany B. Campbell, Levi A. Garraway, Adam Shlien, Garrett Michael Frampton, Franklin W. Huang, Juliann Chmielecki, Zachary Rockow Chalmers, Mark Kennedy, Daniel S. Lieber, Caitlin F. Connelly, Laurie M. Gay, Riley Charles Ennis, Alexa Betzig Schrock, Yuting He, James Sun, Steven M. Roels, Geoffrey A. Otto, Jeffrey S. Ross, P. J. Stephens, Mark Kennedy, Phillip J. Stephens
2017-04-13

PMS2 promoter mutationscomprehensive genomic profilingmicrosatellite instabilitytumor mutational burdenwhole-exome sequencing
BACKGROUND: High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC). The distribution of TMB and the subset of patients with high TMB has not been well characterized in the majority of cancer types. METHODS: In this study, we compare TMB measured by a targeted comprehensive genomic profiling (CGP) assay to TMB measured by exome sequencing and simulate the expected variance in TMB when sequencing less than the whole exome. We then describe the distribution of TMB across a diverse cohort of 100,000 cancer cases and test for association between somatic alterations and TMB in over 100 tumor types. RESULTS: We demonstrate that measurements of TMB from comprehensive genomic profiling are strongly reflective of measurements from whole exome sequencing and model that below 0.5 Mb the variance in measurement increases significantly. We find that a subset of patients exhibits high TMB across almost all types of cancer, including many rare tumor types, and characterize the relationship between high TMB and microsatellite instability status. We find that TMB increases significantly with age, showing a 2.4-fold difference between age 10 and age 90 years. Finally, we investigate the molecular basis of TMB and identify genes and mutations associated with TMB level. We identify a cluster of somatic mutations in the promoter of the gene PMS2, which occur in 10% of skin cancers and are highly associated with increased TMB. CONCLUSIONS: These results show that a CGP assay targeting ~1.1 Mb of coding genome can accurately assess TMB compared with sequencing the whole exome. Using this method, we find that many disease types have a substantial portion of patients with high TMB who might benefit from immunotherapy. Finally, we identify novel, recurrent promoter mutations in PMS2, which may be another example of regulatory mutations contributing to tumorigenesis.
1
A CGP assay targeting approximately 1.1 Mb of coding genome can accurately assess TMB and identify patients who may benefit from immune checkpoint immunotherapy.
2
A cluster of recurrent PMS2 promoter mutations occurs in 10% of skin cancers and is strongly associated with increased TMB.
3
Across 100,000 cancer cases and over 100 tumor types, a subset of patients has high TMB in nearly every cancer type, including rare tumors.
4
Comprehensive genomic profiling (CGP) TMB measurements strongly reflect whole-exome sequencing results, while variance increases substantially below 0.5 Mb of sequencing territory.
5
TMB increases significantly with age, showing a 2.4-fold difference between patients aged 10 and 90 years.

Tumor mutational burden across 100,000 human cancer cases spanning over 100 tumor types

The distribution, measurement variance, age dependence, microsatellite instability relationship, and somatic genetic determinants of tumor mutational burden

Publication Details
Publication Date
2017-04-13
Journal
Publisher
ISSN
Cited by
3593
Access Type
Author Information
Authors
Uri Y. Tabori
Siraj Mahamed Ali
Vincent A. Miller
David A. Fabrizio
Geoff A. Otto
Jared R. White
Brittany B. Campbell
Levi A. Garraway
Adam Shlien
Garrett Michael Frampton
Franklin W. Huang
Juliann Chmielecki
Zachary Rockow Chalmers
Mark Kennedy
Daniel S. Lieber
Caitlin F. Connelly
Laurie M. Gay
Riley Charles Ennis
Alexa Betzig Schrock
Yuting He
James Sun
Steven M. Roels
Geoffrey A. Otto
Jeffrey S. Ross
P. J. Stephens
Mark Kennedy
Phillip J. Stephens
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%